| JYSB2500040 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2025-02-18 | | Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | | | view |
| JYSZ2200038 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | License Renew | 2022-08-03 | | Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | | | view |
| JYSB2101218 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2021-12-31 | | Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | | | view |
| JYSB2101110 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2021-08-25 | | Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | | | view |
| JYSB2000287 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2020-06-19 | 勃林格殷格翰（中国）投资有限公司 | Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | Filed | 2020-06-22 | view |
| JYSB1900280 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2019-10-16 | 勃林格殷格翰（中国）投资有限公司 | Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | Certificate Issued | 2020-09-27 | view |
| JYSB1800276 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2018-12-06 | 勃林格殷格翰（中国）投资有限公司 | Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | Filed | 2018-12-13 | view |
| JYSB1800205 | 依达赛珠单抗注射液 | idarucizumab | Injection | Biological Products | Supplementary Application | 2018-09-25 | 勃林格殷格翰（中国）投资有限公司 | Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | Filed | 2018-09-28 | view |
| JYSB1600270 | BI655075 | idarucizumab | Injection | Biological Products | Supplementary Application | 2016-12-26 | 勃林格殷格翰国际贸易（上海）有限公司 | Boehringer Ingelheim International Trading (Shanghai) Co Ltd;Boehringer Ingelheim International GmbH;Boehringer Ingelheim Pharma Gmbh & Co KG | Certificate Issued | 2017-03-14 | view |
| JXSL1600015 | Idarucizumab注射液 | idarucizumab | Injection | Biological Products | Import Drug Application | 2016-03-25 | 勃林格殷格翰（中国）投资有限公司 | Boehringer Ingelheim (China) Investment Co Ltd;Boehringer Ingelheim International GmbH | Certificate Issued | 2018-06-15 | view |
| JXSL1400013 | BI655075 | idarucizumab | Injection | Biological Products | Import Drug Application | 2014-03-17 | 勃林格殷格翰国际贸易（上海）有限公司 | Boehringer Ingelheim International Trading (Shanghai) Co Ltd;Boehringer Ingelheim International GmbH | Certificate Issued | 2016-08-08 | view |
